GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.

Berkeley, CA, USA

South San Francisco, CA, USA

GenEdit

Biotechnology

Delivery service

Genetics

Therapeutics

	
Bow is a venture capital fund bridging the best of academia, business, and entertainment. We formed to leverage the discoveries of the University of California with the business potential of Silicon Valley and entertainment.

Bow Capital

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Bow Capital Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Bow Capital network as they come up.

You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Bow Capital company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Build a legacy